| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mu-Qi Wang, Ya-Ping Li, Meng Xu, Yan Tian, Yuan Wu, Xin Zhang, Juan-Juan Shi, Shuang-Suo Dang and Xiao-Li Jia |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
31500650, 81902449 |
| Key Research & Development Program-Social Development of Shaanxi Province |
2020SF-063 |
| Shaanxi Key Research and Development Plans |
2021SF-227 |
|
| Corresponding Author |
Xiao-Li Jia, Doctor, Chief Doctor, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157 Xiwu Road, Xincheng District, Xi’an 710004, Shaanxi Province, China. drjxl.123@xjtu.edu.cn |
| Key Words |
VCAN; Hepatocellular carcinoma; Hepatitis B virus; Immune checkpoints; Tumor microenvironment |
| Core Tip |
VCAN expression is significantly higher in hepatocellular carcinoma (HCC) tumor tissue than in adjacent tissue, and high VCAN level may be a possible biomarker for the diagnosis and prognosis of HCC. VCAN is associated with hepatitis B e antigen in hepatitis B virus infected patients. VCAN may play a role in HCC through the extracellular matrix signaling pathway and inflammatory immune response, and is a potential biomarker for immune checkpoint (programmed cell death protein 1/cytotoxic T lymphocyte antigen 4) inhibitors. |
| Publish Date |
2022-10-14 12:54 |
| Citation |
Wang MQ, Li YP, Xu M, Tian Y, Wu Y, Zhang X, Shi JJ, Dang SS, Jia XL. VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors. World J Gastrointest Oncol 2022; 14(10): 1933-1948 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i10/1933.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i10.1933 |
